{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:31:19Z","timestamp":1794346279116,"version":"4.9.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mucosalimmunology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mucosal Immunology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41385-020-00347-6","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T12:04:40Z","timestamp":1601553880000},"page":"479-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-1605","authenticated-orcid":false,"given":"Rachel Y.","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin T.","family":"Shearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Orlicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla D.","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica E.","family":"Alexeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi M.","family":"Lanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Kostelecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Colgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair P.","family":"Fennimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41385-020-00347-6_bib1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"10.1038\/s41385-020-00347-6_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"10.1038\/s41385-020-00347-6_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","article-title":"Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci","volume":"57","author":"Folseraas","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1038\/s41385-020-00347-6_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00281-009-0154-7","article-title":"The immunobiology of primary sclerosing cholangitis","volume":"31","author":"Aron","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"10.1038\/s41385-020-00347-6_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"10.1038\/s41385-020-00347-6_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S186097","article-title":"A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis","volume":"12","author":"Vaughn","year":"2019","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1038\/s41385-020-00347-6_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"U. Eur. Gastroenterol. J."},{"key":"10.1038\/s41385-020-00347-6_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke","year":"2016","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/s41385-020-00347-6_bib10","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S1590-8658(18)30266-4","article-title":"PC.01.8 the aesop trial: a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis","volume":"50","author":"Larusso","year":"2018","journal-title":"Digestive Liver Dis."},{"key":"10.1038\/s41385-020-00347-6_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.27180","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)","volume":"60","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/s41385-020-00347-6_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1038\/s41385-020-00347-6_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2009.02.046","article-title":"Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells","volume":"137","author":"Eksteen","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1038\/s41385-020-00347-6_bib15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20041035","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"200","author":"Eksteen","year":"2004","journal-title":"J. Exp. Med"},{"key":"10.1038\/s41385-020-00347-6_bib16","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2019.05.006","article-title":"Return to sender: lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis","volume":"71","author":"de Krijger","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1038\/s41385-020-00347-6_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell"},{"key":"10.1038\/s41385-020-00347-6_bib19","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.clinre.2011.04.014","article-title":"Will we ever model PSC? - \u201cit's hard to be a PSC model!\u201d","volume":"35","author":"Pollheimer","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1038\/s41385-020-00347-6_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1038\/s41385-020-00347-6_bib21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/j.1478-3231.2009.02044.x","article-title":"Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice","volume":"29","author":"Jahnel","year":"2009","journal-title":"Liver Int."},{"key":"10.1038\/s41385-020-00347-6_bib22","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.2174\/13894501113149990158","article-title":"Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease","volume":"14","author":"Bamias","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1038\/s41385-020-00347-6_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gut.36.4.604","article-title":"Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis","volume":"36","author":"Bloom","year":"1995","journal-title":"Gut"},{"key":"10.1038\/s41385-020-00347-6_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"10.1038\/s41385-020-00347-6_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26447","article-title":"Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis","volume":"58","author":"Katt","year":"2013","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib26","doi-asserted-by":"crossref","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","article-title":"Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon","volume":"312","author":"Ward","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1038\/s41385-020-00347-6_bib27","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/gast.1996.v111.pm8698195","article-title":"Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene","volume":"111","author":"Van Nieuwkerk","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1038\/s41385-020-00347-6_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6793-7-10","article-title":"Inflammatory cytokines induce MAdCAM-1 in murine hepatic endothelial cells and mediate alpha-4 beta-7 integrin dependent lymphocyte endothelial adhesion in vitro","volume":"7","author":"Ando","year":"2007","journal-title":"BMC Physiol."},{"key":"10.1038\/s41385-020-00347-6_bib31","doi-asserted-by":"crossref","first-page":"C272","DOI":"10.1152\/ajpcell.00406.2003","article-title":"Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells","volume":"288","author":"Ogawa","year":"2005","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1038\/s41385-020-00347-6_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1038\/s41385-020-00347-6_bib33","doi-asserted-by":"crossref","unstructured":"Van den Bossche, L. et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl. Environ. Microbiol.83,\u00a0e02766\u201316\u00a0(2017).","DOI":"10.1128\/AEM.02766-16"},{"key":"10.1038\/s41385-020-00347-6_bib34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/MIB.0b013e318286fa61","article-title":"Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1038\/s41385-020-00347-6_bib35","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.12688\/f1000research.12449.1","article-title":"Recent advances in understanding bile acid homeostasis","volume":"6","author":"Chiang","year":"2017","journal-title":"F1000Res"},{"key":"10.1038\/s41385-020-00347-6_bib36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000450916","article-title":"The role of inflammation in the mechanisms of bile acid-induced liver damage","volume":"35","author":"Cai","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1038\/s41385-020-00347-6_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mam.2017.04.002","article-title":"Bile acids and colon cancer: Is FXR the solution of the conundrum?","volume":"56","author":"Gadaleta","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"10.1038\/s41385-020-00347-6_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1038\/s41385-020-00347-6_bib39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib40","first-page":"1684","article-title":"Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps","volume":"58","author":"Batta","year":"1998","journal-title":"Cancer Res"},{"key":"10.1038\/s41385-020-00347-6_bib41","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1113\/jphysiol.2013.252544","article-title":"Ursodeoxycholic acid attenuates colonic epithelial secretory function","volume":"591","author":"Kelly","year":"2013","journal-title":"J. Physiol."},{"key":"10.1038\/s41385-020-00347-6_bib42","doi-asserted-by":"crossref","first-page":"G259","DOI":"10.1152\/ajpgi.00354.2017","article-title":"Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms","volume":"315","author":"Golden","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1038\/s41385-020-00347-6_bib43","doi-asserted-by":"crossref","first-page":"e0181183","DOI":"10.1371\/journal.pone.0181183","article-title":"Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1038\/s41385-020-00347-6_bib44","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0022-3476(05)81103-5","article-title":"Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis","volume":"117","author":"Colombo","year":"1990","journal-title":"J. Pediatr."},{"key":"10.1038\/s41385-020-00347-6_bib45","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J. Immunol."},{"key":"10.1038\/s41385-020-00347-6_bib46","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"10.1038\/s41385-020-00347-6_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","article-title":"Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases","volume":"62","author":"Duboc","year":"2013","journal-title":"Gut"},{"key":"10.1038\/s41385-020-00347-6_bib48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mam.2017.06.002","article-title":"Interactions between gut bacteria and bile in health and disease","volume":"56","author":"Long","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"10.1038\/s41385-020-00347-6_bib49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"10.1038\/s41385-020-00347-6_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control TH17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"10.1038\/s41385-020-00347-6_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756283X10373176","article-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","volume":"3","author":"Ghosh","year":"2010","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1038\/s41385-020-00347-6_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0049-0172(96)80034-5","article-title":"Adhesion molecules in autoimmune disease","volume":"25","author":"McMurray","year":"1996","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1038\/s41385-020-00347-6_bib53","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/ibd.20501","article-title":"Leukocyte adhesion molecules in animal models of inflammatory bowel disease","volume":"14","author":"Rivera-Nieves","year":"2008","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1038\/s41385-020-00347-6_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00281-009-0167-2","article-title":"Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis","volume":"31","author":"Borchers","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"10.1038\/s41385-020-00347-6_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/363461a0","article-title":"MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1","volume":"363","author":"Briskin","year":"1993","journal-title":"Nature"},{"key":"10.1038\/s41385-020-00347-6_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/331041a0","article-title":"A tissue-specific endothelial cell molecule involved in lymphocyte homing","volume":"331","author":"Streeter","year":"1988","journal-title":"Nature"},{"key":"10.1038\/s41385-020-00347-6_bib57","doi-asserted-by":"crossref","unstructured":"Lynch, K. D. et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin. Gastroenterol. Hepatol.18, 179\u2013187 (2019).","DOI":"10.1007\/s11901-019-00456-2"},{"key":"10.1038\/s41385-020-00347-6_bib58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000454853","article-title":"Therapeutic mechanisms of bile acids and nor-ursodeoxycholic acid in non-alcoholic fatty liver disease","volume":"35","author":"Steinacher","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1038\/s41385-020-00347-6_bib59","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1038\/s41385-020-00347-6_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1038\/s41385-020-00347-6_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-2006-960172","article-title":"MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes","volume":"27","author":"Trauner","year":"2007","journal-title":"Semin Liver Dis."},{"key":"10.1038\/s41385-020-00347-6_bib62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hep.20159","article-title":"BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis","volume":"39","author":"Pauli-Magnus","year":"2004","journal-title":"Hepatology"},{"key":"10.1038\/s41385-020-00347-6_bib63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00535-015-1110-z","article-title":"ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression","volume":"51","author":"Degiorgio","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1038\/s41385-020-00347-6_bib64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00424-006-0062-9","article-title":"Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein)","volume":"453","author":"Oude Elferink","year":"2007","journal-title":"Pflug. Arch."},{"key":"10.1038\/s41385-020-00347-6_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10620-010-1240-3","article-title":"Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis","volume":"56","author":"Hall","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"10.1038\/s41385-020-00347-6_bib66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcmgh.2015.01.006","article-title":"Experimental models of inflammatory bowel diseases","volume":"1","author":"Kiesler","year":"2015","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1038\/s41385-020-00347-6_bib67","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.analchem.5b01556","article-title":"Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry","volume":"87","author":"Sarafian","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1038\/s41385-020-00347-6_bib68","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.1998.00728.x","article-title":"Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines","volume":"114","author":"Dieleman","year":"1998","journal-title":"Clin. Exp. Immunol."}],"container-title":["Mucosal Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41385-020-00347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41385-020-00347-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021922001477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021922001477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41385-020-00347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:10:19Z","timestamp":1761829819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933021922001477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1933021922001477"],"URL":"https:\/\/doi.org\/10.1038\/s41385-020-00347-6","relation":{},"ISSN":["1933-0219"],"issn-type":[{"value":"1933-0219","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis","name":"articletitle","label":"Article Title"},{"value":"Mucosal Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41385-020-00347-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 \u00a9 Society for Mucosal Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}